uated reports of 155 quality problems associated with compounded preparations, including failed sterility and potency testing, many of which have resulted in recalls, patient injury, and death [2] . Multiple outbreaks of infection caused by contaminated medications from compounding pharmacies have been reported [3] [4] [5] [6] [7] ; however, prior to this outbreak, none have involved the multistate distribution of compounded intravenous medication.
Serratia marcescens is an aerobic gram-negative bacillus that is a recognized cause of health care-associated bloodstream infection (BSI). The bacteria thrive in moist environments and have been cultured from a variety of sources throughout health care settings, including multidose medication vials [8] , disinfectants [9] [10] [11] [12] , hand soaps [13] , and the hands and fingernails of health care workers [14, 15] . In 2005, the CDC Division of Healthcare Quality Promotion (DHQP) was notified of 2 S. marcescens bloodstream infection clusters, the first of which occurred in a hospital in Los Angeles County, California, in January 2005, and the second of which occurred among patients in a cardiac and pulmonary specialty hospital in New Jersey (NJ) in March 2005. We report how the identification of these clusters led to the discovery of a multistate outbreak of health care-acquired BSI caused by compounded intravenous magnesium sulfate (MgSO 4 ) solution and the relevant issues surrounding the regulation of compounding pharmacies in the United States.
LOS ANGELES INVESTIGATION
In January 2005, infection-control personnel at a Los Angeles County hospital (LA Hospital) identified an increase in the number of S. marcescens BSIs after cardiac procedures. When no obvious source could be identified, the CDC DHQP was asked to investigate.
Methods. To confirm whether the S. marcescens BSI cluster represented an outbreak, we reviewed microbiology records at the LA Hospital for cultures yielding S. marcescens from January 2004 through January 2005 and compared the S. marcescens BSI rate from the year before the outbreak with the rate during the outbreak. All recent S. marcescens isolates from the LA Hospital had been analyzed using PFGE by the Los Angeles County Public Health Laboratory staff prior to our arrival. Because all case patients had been hospitalized in the cardiac surgery unit (CSU) prior to infection, a case was defined by the following criteria: a culture-confirmed S. marcescens BSI [16] in a patient treated in the CSU in January 2005, with the isolate demonstrating a PFGE pattern indistinguishable from the outbreak strain. To determine risk factors for illness, we conducted a matched case-control study. Control subjects were defined as patients who did not have a documented S. marcescens BSI and who were present in the CSU within 4 h of the matched case patient having a blood culture positive for S. marcescens. Each case patient was matched to 3 randomly selected control subjects. Data from the 24-h period prior to the case patient having a culture positive for S. marcescens were collected for both case patients and matched control subjects. Factors assessed included demographic and clinical characteristics of the patients and exposure to devices, procedures, medications, and personnel in the operating room and CSU.
We also reviewed CSU and operating room infection-control practices and policies and interviewed personnel in groups. On the basis of information from observation and interviews, environmental samples were obtained for culture. Cultured sites included sinks, counters and other surfaces, cleaning solutions, soap, water, ice, and multidose medication vials (open and unopened) from the operating room and CSU. Of note, medications used during the outbreak were no longer available for testing, with the exception of insulin. Environmental specimens from the LA Hospital were screened for S. marcescens at the CDC DHQP laboratory (Atlanta, GA).
All data were collected on standardized forms and analyzed using SAS software (SAS Institute). Cochran-Mantel-Haenszel ORs and 95% CIs were calculated to compare categorical variables, and the Wilcoxon 2-sample test using t approximation was used to compare continuous variables.
Results. a P values and 95% CIs are based on x 2 analysis for categorical variables and the Wilcoxon 2-sample test using t approximation for continuous variables.
NJ INVESTIGATION, MARCH 2005
Methods. We defined a case as S. marcescens BSI occurring in a patient hospitalized in a NJ Hospital from January through March 2005. Cases were identified by review of infection-control, microbiologic, and medical records. To determine common exposures, we reviewed the medical records of case patients for clinical and demographic characteristics and exposure to devices, procedures, and medications. We also reviewed pharmacy procedures, infection-control policies, and practices in the operating room and CSU. All results of environmental cultures performed by infection-control practitioners, including results of culture of medical equipment and samples from opened and unopened bags of intravenous solution, were similarly reviewed.
NJ Hospital clinical and environmental specimens were sent to the NJ Hospital microbiology laboratory for culture using standard methods. A representative sample of S. marcescens isolates from LA Hospital case patients and all isolates from the NJ Hospital (clinical and environmental) were sent to the CDC DHQP laboratory for species confirmation and PFGE analysis [17] [18] [19] .
Results. Five case patients, who received a diagnosis of S. marcescens BSI during 2-10 March 2005, were identified in the NJ Hospital. All were admitted electively to undergo cardiovascular surgical procedures and received intravenous MgSO 4 from compounding pharmacy X within 48 h prior to the onset of BSI signs. Review of infection-control procedures identified no major breaches. Culture of samples of intravenous infusion administered to 1 patient at the time of BSI symptom onset and from the remaining MgSO 4 for that patient yielded S. marcescens. Culture of a sample from an unopened bag of intravenous MgSO 4 in the same lot also yielded S. marcescens..
S. marcescens isolates from all patients at the NJ Hospital
and from the open and unopened bags of MgSO 4 had indistinguishable PFGE banding patterns from those of isolates from the 6 case patients at LA Hospital. The epidemiologic and molecular links of the 2 outbreaks prompted a multistate investigation.
MULTISTATE CASE-FINDING AND COMPOUNDING PHARMACY X INVESTIGATIONS

Methods
For the multistate investigation, we defined a suspect case as S. marcescens BSI occurring within 72 h after receipt of intravenous MgSO 4 supplied by compounding pharmacy X from January 2004 through March 2005. We defined a confirmed case as a suspect case with a clinical isolate demonstrating a PFGE banding pattern related to the outbreak strain [17, 18] . A possible case was defined as a suspect case with a clinical isolate that was not available for PFGE analysis.
Case-finding was conducted using multiple methods: (1) contact of hospitals that received the known contaminated MgSO 4 lot according to sales records, (2) nationwide alert of public health officials using the CDC's Epidemic Information Exchange and health alert notifications, and (3) review of clinical isolates of S. marcescens from microbiology laboratories at institutions that received contaminated product. Persons reporting suspect cases completed a standard case-report form, which included demographic and clinical characteristics of case patients and the timing, doses, and source of intravenous MgSO 4 received.
CDC staff interviewed representatives of compounding pharmacy X to determine the distribution of the contaminated lots Microbiologic and laboratory methods. A representative sample of S. marcescens isolates from LA Hospital case patients, all isolates from NJ Hospital, and the available isolates from suspect case patients were sent to the CDC DHQP laboratory for species confirmation and PFGE analysis [17] [18] [19] . Sterility testing and culture of samples from unopened MgSO 4 bags was performed by the FDA Northeast Regional Laboratory (Jamaica, NY). All FDA isolates were sent to the CDC DHQP laboratory for PFGE analysis and comparison with the outbreak strain.
Statistical analysis. All data were collected on standardized forms and analyzed using SAS software (SAS Institute) or EpiInfo, version 3.3.2 (CDC). Statistical tests are described in the Part 1 Methods section.
Results
Interviews with representatives from compounding pharmacy X revealed that the initial contaminated lot discovered in NJ (lot A) contained 240 units that were shipped to 5 hospitals in 5 states, including NJ. Two of the remaining 4 hospitals identified case patients with S. marcescens BSI upon notification. Because LA Hospital did not receive MgSO 4 from lot A, we determined that 11 lot was contaminated. Case-finding was subsequently broadened to include cases of S. marcescens BSI occurring after infusion with MgSO 4 from any lot prepared and distributed by compounding pharmacy X from January 2004 to the present time.
A total of 50 suspect cases in 11 states (figures 1 and 2) were identified. Eighteen cases met the definition for confirmed S. marcescens BSI. Seven of 50 case patients did not have isolates available for testing and were considered to have possible cases. The remaining 25 isolates were genetically unrelated by PFGE and thus excluded. Confirmed cases were diagnosed from 5 January through 26 March 2005 (figure 1) and involved 5 states: California (6 cases), NJ (5 cases), North Carolina (3 cases), New York (2 cases), and Massachusetts (2 cases). The clinical characteristics of the 18 confirmed case patients are described in table 2.
S. marcescens isolates from the 18 case patients and unopened bags of MgSO 4 demonstrated genetically related PFGE banding patterns (within 3 bands difference), supporting our hypothesis that the MgSO 4 was the source of the outbreak (figure 2) [18] . The FDA performed sterility testing on 20 units from lot A, 3 (15%) of which yielded growth of S. marcescens, which was confirmed by PFGE to be indistinguishable from the outbreak strain. Sterility testing of samples from unopened bags of MgSO 4 from other lots revealed that 2 (10%) of 20 units from an additional lot (lot B) yielded growth of multiple gram-negative bacteria, including Pseudomonas aeruginosa, Alcaligenes xylosoxidans, Acinetobacter lwoffii, and Chromobacterium violaceum. Case-finding for cases of infection with the latter 3 organisms among purchasers of MgSO 4 from compounding pharmacy X identified no related cases of BSI. Specific lot numbers of MgSO 4 administered to patients were only available for NJ case patients.
Compounding pharmacy X is operated as an outsourcing pharmacy (i.e., a pharmacy that provides medications to other pharmacies) and prepared compounded products for hospitals in every state, except Ohio. The pharmacy compounded MgSO 4 in multiple doses and purchased sterile components from pharmaceutical manufacturers. Each lot of 50-mL admixtures of MgSO 4 consisted of 240 units, and 1 lot was typically sent to multiple facilities. No recent changes in the compounding process were reported by the company. The State Board of Pharmacy, the FDA, and compounding pharmacy X representatives each investigated the facility where the product was prepared to determine the source of contamination. The pharmacy did not test and retain samples of each lot for sterility, and no definitive source could be identified.
On the basis of the results of the Los Angeles and NJ investigations, compounding pharmacy X voluntarily recalled lot 4 because of "a potential lack of sterility assurance for these products" [20] . The firm voluntarily ceased production and distribution of the product. No additional cases of S. marcescens BSI associated with compounding pharmacy X MgSO 4 were identified after the second product recall.
DISCUSSION
We describe a national health care-associated outbreak of S. marcescens BSI caused by contaminated intravenous medication produced by a compounding pharmacy. Initially, it appeared that compounding pharmacy X was a pharmaceutical manufacturer; however, the investigation revealed that the company adhered to the limited regulations of a compounding pharmacy. This presented challenges associated with oversight, outbreak detection, and authority to intervene during an outbreak that do not occur with pharmaceutical manufacturers. The multistate distribution of large quantities of sterile compounded medications, coupled with critical differences between pharmaceutical compounding and manufacturing, have important patient safety implications for clinicians, pharmacists, public health officials, and the general public.
Because of the concern that some pharmacies were manufacturing medications without prescriptions under the limited regulation of compounding [21, 22] , the FDA released guidance to assist the investigation of compounding pharmacies [21] . These guidelines, however, are not enforceable by law. Rather, compounding pharmacies are regulated by state laws governing the practices of pharmacies. Two of 9 activities considered to be inappropriate for compounding pharmacies that are outlined in the FDA document are relevant to this investigation.
The first act deemed to be inappropriate by the FDA is the compounding of drugs in anticipation of receiving prescriptions, except in very limited quantities in relation to the amount of drugs compounded after receiving valid prescriptions. Compounding pharmacy X stated during the investigation that they did not receive prescriptions for individual patients on which to base anticipatory batches, nor had they ever received them. After inspection of compounding pharmacy X, the State Board of Pharmacy issued a warning notice indicating that compounding pharmacy X was not operating as a pharmacy because of preparation of anticipatory batches of compounded medication without prescriptions. This represents a failure to operate in conformance with applicable state laws regulating pharmacy practice-the second activity deemed inappropriate by the FDA.
Several factors delayed the detection of this outbreak. Most intravenous solutions are purchased from wholesale distributors who purchase these products from pharmaceutical manufacturers that adhere to FDA requirements. The MgSO 4 from compounding pharmacy X appeared to be similar to manufactured products, which may have delayed suspicion of the solution as a source of infection at the LA Hospital. Neither hospital pharmacy was aware that the product was compounded; there was no specific indication on the package labeling, and the company's Web site did not specify that the product was compounded. Of note, a similar product in the same dose is available from a pharmaceutical manufacturer [23] that differs from the compounding pharmacy X product only in total volume (100 mL vs. 50 mL). Prior to this outbreak, many involved clinicians, pharmacy staff, and public health officials were unaware of the differences between compounded and manufactured sterile products. One important quality-control issue that separates pharmaceutical manufacturing from compounding is the requirement for manufacturers to test and retain samples of each lot of intravenous medication for sterility. The US Pharmacopeial Convention, an FDA-recognized compendium that sets standards for pharmacies involved in the compounding of sterile products [2, 24] , states that compounders are responsible for ensuring that compounded sterile products are "correctly sterilized" [2, p. 1930] . However, there is no requirement for sterility testing of the final compounded product or for retention of product for future sterility testing. Because no MgSO 4 was retained or tested for sterility after production by compounding pharmacy X, the FDA and the CDC had to locate remaining unopened product from hospitals to perform testing, which may have further delayed identification of the outbreak.
Another important distinction between compounding pharmacies and manufacturers is manipulation of previously sterilized components by compounders, leading to an increased likelihood of the final product being contaminated. MgSO 4 production by compounding pharmacy X required individual handling of each bag by a pharmacist, which is standard practice for a compounding pharmacy. Manufacturers produce large quantities of pharmaceuticals with automated machines, decreasing human handling, and most admixing and dilution steps occur prior to final sterilization. When contamination occurs during manufacture, it is more likely to be detected by sterility testing at the end of the process. The individual handling of the product during compounding increases the likelihood of intermittent contamination, because each unit may not be subject to the same breach in infection control. An outbreak resulting from intermittent contamination is less likely to cause an obvious cluster of disease, making an outbreak difficult to detect. The widespread distribution of contaminated product to multiple states further decreases the likelihood of outbreak detection, because several state health departments need to be simultaneously alerted.
A possible source of contamination in this outbreak was the hands of the compounding pharmacist(s). Several facts support this mechanism. First, only 50-mL bags of the product were involved, despite the fact that several other larger dose bags of MgSO 4 are made by the company using the same process and components. Because of its small size, a 50-mL bag of solution is difficult to manipulate without touching the entry port where medication is injected. Secondly, the discovery of polymicrobial contamination of lot B with multiple gram-negative species, several of which are typically environmental organisms, supports product handling as the most likely mode of transmission.
Several limitations to this investigation exist. Neither the FDA nor compounding pharmacy X identified the source of contamination of the MgSO 4 during the compounding process; however, some evidence suggests contamination from product handling. Secondly, P. aeruginosa, one of the organisms identified in lot B, is too commonly isolated to perform adequate case-finding nationally. Therefore, it is likely that the number of BSI cases caused by the contamination of this product presented in our article is an under-representation of the actual number.
Despite having generally lower quality-control standards than pharmaceutical manufacturers, compounding pharmacies are increasingly used by hospitals as a source of parenteral medications-often because of their lower cost. Hospital pharmacists and administrations should be aware of the risks associated with compounded sterile medications and should consider them before purchasing the products. Investigators should also take these risks into account when investigating an outbreak of BSI.
